Home / Transcripts / Ipca Laboratories Limited (IPCALAB) · June 1, 2026

Ipca Laboratories Limited (IPCALAB) Earnings Call Transcript

June 1, 2026

National Stock Exchange of India IN Health Care Pharmaceuticals earnings 37 min

Earnings Call Speaker Segments

Operator operator
#1

Good day, everyone, and welcome to the Ipca Labs Q4 FY 2026 earnings call, brought to you by DAM Capital Advisors Limited. Just a reminder that every participant line will be in listen-only mode, and once the presentation wraps up, you'll have a chance to ask questions. If you need help at any point during this call, just press star then zero on your touch-tone phone to signal an operator. Please be aware that this conference is being recorded. I'll now turn the conference over to Mr. Nitin Agarwal of DAM Capital Advisors Limited. Thank you, and the floor is yours, sir.

Nitin Agarwal analyst
#2

Thank you, and hi — good afternoon, everyone. A very warm welcome to the Q4 FY 2026 post-results earnings call for Ipca Labs Limited, which DAM Capital Advisors Limited is hosting. Joining us on today's call, representing Ipca Lab management, are Mr. A.K. Jain, Managing Director, and Mr. Harish Kamath, Corporate Counsel and Company Secretary. I'll now hand things over to Mr. Jain for his opening comments, after which he'll open the floor for questions. Please go ahead, sir.

A.K. Jain executive
#3

Thanks, Nitin. DAM Capital for arranging this call. The hearing call today and the discussions, the answers provided might contain some forward-looking statements grounded in what we currently expect for the business. This has to be looked at together with the risks that the pharmaceutical business faces. What we actually achieve financially in the future could be different from what is projected or foreseen. You may form your own judgment about the information shared during the call. Our domestic formulation business in Q4 FY 2026 has delivered growth of roughly 12%. That business stood at approximately INR 853 crore versus INR 764 crore in Q4 2025. As of mid-March 2026, Ipca's rank continued to stay at 16. Even so, we have slightly bettered our market share to 2.09% versus 2.08% in mid-December 2025. Six of our brands are appearing among the industry's top 300 brands, and in both the chronic and acute segments, we keep outperforming the market. Overall, for FY 2026, our domestic business grew by approximately 10% to approximately INR 3,817 crore versus INR 3,455 crore in FY 2025. Our export formulation business delivered growth of approximately 9% for the financial year 2026 to approximately INR 2,083 crore from INR 1,919 crore. The promotional business for the quarter delivered growth of approximately 14%, and for the whole year as well, this business delivered growth of approximately 14%.

A.K. Jain executive
#4

For the full financial year, our promotional business—meaning promotional branded plus export—came in at roughly INR 664 crore, compared with INR 582 crore a year earlier. On generics, leaving tenders aside, we saw growth of about 17% for the year, reaching approximately INR 1,149 crore versus INR 982 crore in FY 2025. Institutional business fell over the year, landing near INR 270 crore, down from about INR 355 crore last financial year. And in the final quarter of this year as well, that business slipped to roughly INR 74 crore, compared with INR 111 crore in Q4 FY 2025. For the API segment, full-year growth was about 10%. That business now stands at approximately INR 1,396 crore, versus INR 1,266 crore for FY 2026. At the consolidated level, the company's overall business in FY 2026—March 2026—grew roughly 6%, to about INR 2,388 crore from around INR 2,274 crore. Consolidated revenue for the entire year rose approximately 8%, to roughly INR 9,646 crore, against INR 8,940 crore for financial year 2025. Standalone EBITDA margin at Ipca in Q4 improved to about 25.27%, compared with 21.19% in Q4 FY 2025.

A.K. Jain executive
#5

That marks a gain of roughly 4.08%. Across the financial year March 2026, the standalone EBITDA margin for the company overall rose to approximately 25.18%, compared with 22.66% in March 2026 — an overall enhancement of about 2.52% — and versus our guidelines for the financial year, we have improved margins significantly on an overall basis. Consolidated Ipca Q4 FY 2026 EBITDA margin came in better at roughly 20.52%, versus 18.24% in Q4 FY 2025, which is an improvement of about 2.28%. Over the whole financial year, EBITDA margins for March 2026 climbed to approximately 20.72%, compared with 19.94% in March 2025, an improvement of roughly 1.78%. Against our 20% guideline for FY 2026 overall, we have delivered better margins. Now that the broad numbers are on the table, I'll open the floor to questions from the participants.

Operator operator
#6

Thanks a lot. At this point we'll open things up for questions and answers. If you'd like to pose a question, just hit star and one on your touchtone phone. Should you want to drop out of the question queue, press star and two. As far as concerned, requested to use while asking a question. Ladies and gentlemen, we'll pause briefly while the question queue comes together. Our first question is from Aanchal Jalan at Lotus Wealth. Go right ahead.

Aanchal Jalan analyst
#7

Hi there. Thanks for the question. Sir, if we're aiming for 15%-20% growth over the next two to three years, how many molecules do you figure we need to launch each year? Since older molecules will face tougher competition, and price erosion is occurring there as well. How many launches do you think we ought to be doing in a year? Second, what does our product pipeline look like for Q1 and Q2 of FY 2027? Yeah, that's my question.

A.K. Jain executive
#8

On the old molecules, we really aren’t seeing any price erosion as such. Our usual approach is to implement a price increase of roughly 5%-6% each year, depending on what competitors are doing in the marketplace as well. That approach will keep going that way. When it comes to the domestic market, we don’t launch too many products in a year. Every division has about two or three power brands, and then each division also has support brands. At most, within each division, we might launch one product or a line extension here and there. If we have 20 divisions in the year, then in the domestic market we should be launching around 18 to 20 products. That has been our business philosophy, because the more products you launch, the more people’s attention gets diluted. That leads to an overall loss of focus on your power brands. We normally don’t launch too many products into the marketplace. On generics, let’s say we currently market around eight products in the U.S., and I think this year as well, maybe around six to eight products will be commercialized in the current financial year.

A.K. Jain executive
#9

When it comes to Europe and other markets, conditions differ from one market to another. Typically, in generics we bring out 3 to 4 products per market annually. That reflects where we stand overall.

Aanchal Jalan analyst
#10

All right. Sir, regarding Unichem specifically, six to eight products, correct?

A.K. Jain executive
#11

Unichem also has a solid pipeline, and I believe they ought to be launching a minimum of 5 to 6 products this year.

Aanchal Jalan analyst
#12

You mean all of FY 2027?

A.K. Jain executive
#13

Yes, that segment comes from Ipca.

Aanchal Jalan analyst
#14

Alright, thanks.

Operator operator
#15

Thanks. The next question is from Surya Patra at PhillipCapital. Go ahead, please.

Surya Patra analyst
#16

Yeah. Thanks for giving me the chance, sir, and congratulations on those strong numbers. Sir, my first question concerns the U.S. business. Since these are full year financials, is it possible to say what U.S. revenue we would have generated out of Ipca? And what outlook are we giving for next year?

A.K. Jain executive
#17

Alright, one minute. So overall, when you look at the consolidated figures across the whole business — Ipca U.S.A. and Unichem U.S.A. combined — I believe the U.S. did roughly INR 428 crore of business this quarter, versus INR 388 crore in Q4 of last year. That works out to about 10% growth. Then, on a full financial year basis, the U.S. business comes in at approximately INR 1,567 crore, compared with INR 1,379 crore the prior year. On a consolidated basis, the U.S. delivered growth of roughly 14%.

Surya Patra analyst
#18

Also, sir, could you give us a sense of the growth you've been seeing for FY 2026, mainly in the key markets such as Europe, Africa, CIS, Australia, and so on?

A.K. Jain executive
#19

So India, I'd say, ought to grow at roughly 12%-13% this financial year. The CIS market is going to come in at about 10%-11%. For the overall promotional market, we're expecting growth of something like 12%-13%. The overall generic market should also see growth in that 12%-13% range, and that includes the U.S. as well. Then for the company overall, taking Unichem into account and putting everything together, we should manage roughly 12%-13% growth on a consolidated basis. On the EBITDA side, we're at 20.7% right now on a consolidated basis, and I think it should land at approximately 22%, or 22.3%, something along those lines, more or less.

Surya Patra analyst
#20

Alright, the next item concerns gross margin, sir. As a matter of fact, we've witnessed a robust uptick. Across the entire year as well, there's a sort of better performance that we've observed. Look at what might be credited for this better performance — is it the benefit from currency, or is it synergy, or is it an improvement in product mix, with the U.S. picking it up? What would have played a part in this margin gain, and how sustainable would the gross margin be?

A.K. Jain executive
#21

If we consider it on a standalone basis, versus growth of roughly 10%, our total material cost is down by roughly 2%.

Surya Patra analyst
#22

Thanks.

A.K. Jain executive
#23

For the full year as a whole—well, really from February onward. Before that, material prices in general held fairly stable. We didn't see much fluctuation where material cost was concerned for roughly the first 11 months, let's say across the entire financial year, since we keep certain stocks on hand. On the consumption side, not a great deal. The exception was February and March, when solvent prices and certain other materials saw supply chain disruption—things like ammonia and various others, acid alkali—quite a few of those materials went up. A small portion of material cost rose during February and March, in Q4 of this financial year, on a standalone basis, if you look at the numbers. The overall margin improvement comes largely from changes in product mix.

Surya Patra analyst
#24

Alright.

A.K. Jain executive
#25

When the domestic business performs well, the ROW market business also performs well. The share of the cardiac business has risen, and overall, the generic business, which is occurring in most markets, has also delivered better overall margins for us. Even on the API side, we have improved overall margins. That has produced overall margin improvement on a standalone basis. Where Unichem is concerned, their overall EBITDA margins have fallen from 12% to around 8%, and their turnover has not increased. Because of that, otherwise, the EBITDA margins improvement for the consolidated business would have been even higher.

Surya Patra analyst
#26

All right, just one final point, sir. As for that supply chain disruption, or any effect on raw material availability or price increases, is that situation essentially behind us now, or might the current quarter or the period after it still see some impact in FY 2027?

A.K. Jain executive
#27

Prices have gone up quite a bit now — a meaningful increase. Take packaging material: aluminum is higher, and PVC and PVDC have risen substantially. On solvent pricing, costs remain 40%-50% above what we paid in January or earlier in the financial year as a whole. Many other APIs have also become more expensive, again because something or other in the supply chain has been disrupted. All told, if petroleum prices stay on their current path, I'd expect overall material cost to climb by roughly 10%-12%. That's the sort of increase the market is seeing right now. For instance, a simple product like paracetamol has risen considerably, and metformin has risen considerably. Those moves are far bigger than the figure I just mentioned — I'm referring to the overall picture.

Surya Patra analyst
#28

Alright.

A.K. Jain executive
#29

All in all, in the marketplace there's an increase of roughly 10%-12% overall.

Surya Patra analyst
#30

In practice, what we've seen is that output prices have risen by more than input costs.

A.K. Jain executive
#31

I'd say those input costs have risen. And again, sir, on the output side — for instance with API, what we're selling today, the whole cost increase gets passed along to consumers or buyers. No problem there. On the domestic market, for products under price control, prices stay at the same level. You can't raise even INR 0.01 on those. Overall, for the other decontrolled products, versus the roughly 5% price increase we're taking — given the total rise in input costs, this year's price increase may be somewhat higher, perhaps around 6%-7%, to offset the price increase that has occurred in the marketplace. That will fully offset the entire overall cost rise present in the marketplace. On the generic market as well, arrangements there are somewhat longer term; we're taking it up with the buyers and raising prices wherever possible. I don't foresee much of that impact materializing. There could be perhaps a half a percent point increase, or maybe a 0.75% increase, in material cost. I don't think that will significantly disturb my EBITDA margin in the current year, because, again, the product mix change is at play.

A.K. Jain executive
#32

On the whole, your margin — and so, taking into account the projections plus the guidance for the EBITDA margin across the entire year — is set to shift by roughly 1%-1.25% during this financial year. Where before, we kept referring to an EBITDA margin gain of about 1.5% or slightly above that. That somewhat reduced guidance stems purely from material cost. Should petroleum prices begin climbing again, or move lower, then margins might in fact turn out better still.

Surya Patra analyst
#33

Yes, sir. Thank you, sir. I wish you all the best.

A.K. Jain executive
#34

Appreciate it.

Operator operator
#35

Thanks. The next question is from Rajkumar Vaidyanathan at RK Investments. Please go ahead.

Rajkumar Vaidyanathan analyst
#36

Good afternoon, and thanks for the chance to ask. Sir, I’d just like to hear the outlook for the Unichem business. When do you think margins will improve?

A.K. Jain executive
#37

During the last financial year, Unichem's U.S. business didn't grow. The main reason is that they lost some market share in certain high-volume businesses. They've started regaining that share again, and I think in the current financial year their U.S. business should grow by around 10%. Hopefully, margins will move up along with that. They performed well in the European market last financial year. We also see, from that standpoint going forward, that the business will improve and margins will improve there as well. In addition, they incurred certain additional costs last financial year related to their Ireland facility, where manufacturing was taking place, which has now closed. Those people were also given severance packages and that sort of thing. That cost was also debited. All of that production has been shifted back to India. That too will lead to better margins overall on manufacturing those products here. Also, the overhead cost they were incurring at the Ireland facility, which may be around EUR 4 million to EUR 5 million — that expenditure will also stop in the current financial year. Overall, there will be better improvement in Unichem as well in the current year.

Rajkumar Vaidyanathan analyst
#38

Alright.

A.K. Jain executive
#39

We expect Unichem’s margin may come in at roughly 12%-13% during this financial year, up from that level. Then, starting from that level in later years, as our filings in other markets begin to come through and we begin launching products in those other markets, margins should continue to improve.

Rajkumar Vaidyanathan analyst
#40

So that 12%-13% figure you brought up — is that the total margin for FY 2026/2027?

A.K. Jain executive
#41

Regarding Unichem, yes.

Rajkumar Vaidyanathan analyst
#42

So, taking the whole year together, what about that margin?

A.K. Jain executive
#43

Yeah.

Rajkumar Vaidyanathan analyst
#44

All right. Sir, my second question: Unichem’s inventory looks somewhat elevated. I brought this up last quarter as well. You said certain actions were being taken, and inventory is still roughly at the same level as 25.

A.K. Jain executive
#45

Overall, on the inventory side, I think quite a few steps have already been taken. When you look at the character of the business itself, with Unichem, since it's a U.S. business, supply chain disruptions were all occurring. For certain types of inventory, movement was taking longer by ship and so on. They've begun shipping everything by ship rather than by air. There was a significant volume of air shipment at Unichem — maybe a year ago, roughly 40% of shipments were going by air. Today it's barely about 4% or 5% of shipments moving by air. So the total transit time has improved and lengthened and all of that. Inventory has risen a little because of that, but on the whole, we see no concern of any kind on that front.

Rajkumar Vaidyanathan analyst
#46

Alright.

A.K. Jain executive
#47

The U.S. cycle on its own runs a bit longer, and their business is mostly in the U.S.

Rajkumar Vaidyanathan analyst
#48

Alright.

A.K. Jain executive
#49

When it comes to Ipca, if you take the last two years together — FY 2025 and FY 2026 — by and large, across our inventories and receivables combined, hardly any money has gone into working capital overall. There are accruals overall, and hardly any money has gone into working capital over the last two financial years. Our control is perfect.

Rajkumar Vaidyanathan analyst
#50

Alright.

A.K. Jain executive
#51

Regarding your inventory cycles in general.

Rajkumar Vaidyanathan analyst
#52

Alright, sir. Sir, one final point on the Lyka Labs subsidiary. Its results have been getting worse, since you recorded an impairment for Krebs Bio last year. Will things follow that same path? The reason is that performance is genuinely declining from one quarter to the next.

A.K. Jain executive
#53

I shouldn't really be speaking on behalf of Lyka Labs. On that point, I think you'd need to talk to Lyka Labs directly. Beyond that, from a broad view, they've begun selling their injectables along with animal healthcare products on the market. They've hired a large field force. That takes time. Over the last two years, a significant amount of spending has gone into building a more sustainable business, and because of that — because of the addition of field staff — there are pressures on the P&L account. Still, I think the journey is going very well as far as that animal healthcare team they've launched, and also the critical care team they've launched; both are progressing well, and we don't foresee much concern on that front. Their profitability may currently be lower, but as time passes, these teams will start maturing and the business will start building up, and margins will begin moving up there as well. Okay, sir. Thank you so much.

Operator operator
#54

Thanks. The next person to ask a question is Shashank Krishnakumar from Emkay Global. Go ahead, please.

Shashank Krishnakumar analyst
#55

Hello, and thank you for taking my question. My first question concerns the other expenses line for Unichem, which rose sharply during this quarter. Was that mainly the result of higher R&D spending? And if you could also tell us what the R&D spend came to, for Unichem as well as Ipca standalone, as a percentage of sales for FY 2026.

A.K. Jain executive
#56

I believe the rise in other expenditure at Unichem is mainly attributable to R&D, since they're pursuing some kind of institutional business in the U.S. Technology transfers for around four to five products have been handed to a third-party manufacturer, so those products can be made for the U.S. itself, to supply for government purposes. So this quarter carried roughly INR 10 crore-INR 12 crore of extra spending tied to those technology transfers to the U.S. supporting manufacturer. Beyond that, there's hardly any exceptional cost at all. Other expenditure has by and large gone up solely on that account.

Shashank Krishnakumar analyst
#57

Understood. How much did Unichem and Ipca each spend on R&D in FY 2026, expressed as a share of sales?

A.K. Jain executive
#58

The figure comes in at approximately 3.71%.

Shashank Krishnakumar analyst
#59

Understood. And second, could you share what the growth trends were across the market for the past year, for both branded formulations and generics? Especially since generic revenue rose this quarter, which market was the main driver of that? If you could give some detail on how each individual market has performed.

A.K. Jain executive
#60

For Ipca, domestic grew 12%. Branded formulations rose 14%. Institution fell 33%. The generic market this quarter grew roughly 39%. That covers Ipca overall. For the full financial year, domestic is up about 10%, branded up 14%, institutional down roughly 24%, and generics up around 17%. Those figures are already in the press release. If you look through our press release, all those numbers are shown very clearly there.

Shashank Krishnakumar analyst
#61

Yes, I was hoping for more of those market-specific trends you typically provide. Was there a particular market that drove growth this quarter or during this financial year?

A.K. Jain executive
#62

So, branded is mostly propelled by, say, our CIS market along with the French-speaking African market. India is largely propelled by our pain and cardiac and derma in Europe plus the CNS portfolio that we have. Institutional has mostly fallen off owing to funding constraints that institutions are currently facing. Where generics go, both Europe has performed well, and Australia and New Zealand have performed well. It's broadly all markets, and also the U.S. launches that have happened in the current year. Overall, business has been good where generics are concerned.

Shashank Krishnakumar analyst
#63

Understood, sir. Only the final one, if I may fit it in. Could you comment on how the subsidiaries performed excluding Unichem for this quarter and for the full year.

A.K. Jain executive
#64

Regarding Unichem, I'd say this year has been a difficult one for them. I've already laid out the guidance where Unichem is concerned — how they'll perform during the current financial year. They ought to grow at roughly 10% this financial year. Their EBITDA margins will also improve. Beyond that, we have a domestic subsidiary named Trophic Wellness. They've performed well. I'd say they've contributed significantly. They market nutraceuticals. Their business is perhaps around INR 125 crore, and I think they're generating profit of nearly INR 40 crore plus in overall profit. That. Lyka I've already spoken about. It isn't our subsidiary — it's an associate company. Where the Krebs are concerned, their performance is improving now. One of their plants, located at Nellore, has turned EBITDA positive. As for the other plant, there are certain issues ongoing right now with the pollution departments. Once that gets resolved, I think hopefully we should be able to get that plant to an EBITDA positive kind of number as well. Where European subsidiaries are concerned, we have two subsidiaries in the U.S. One is Ipca formulation marketing company, and the other is Onyx Scientific, which handles the business of rendering research services to the other formulation company.

A.K. Jain executive
#65

Onyx is running into certain problems there, since overall inquiry levels for projects of that type have declined given the current overall environment. Over the past eight, 10 years, this subsidiary has performed very well. During the last one and a half years, some issues have arisen. We are now observing signs of improvement there. The Ipca subsidiary that markets the formulation, especially in the U.K., has posted a loss of roughly GBP 2 million-GBP 3 million. That is largely because in the last financial year, the pricing scenario in that market was very, very bad. We are now again seeing a lot of shortages and an overall improvement in prices. We hope to do better there as well. As for the U.S. subsidiary, there is only one that is the major one, which is Pisgah Labs. There too, a formulation facility is under construction. I think probably in the fourth quarter of the current financial year, they should be ready to commission the plant. Any meaningful turnover coming from there will, I think, arrive only in the next financial year, not in the current financial year. Their API facility is also now seeing a good order position. Hopefully there will be further improvement in that operation as well.

Shashank Krishnakumar analyst
#66

Understood, sir. That's really useful. Thanks, and best of luck.

Operator operator
#67

Thanks. Just a quick reminder for everyone on the line: if you'd like to pose a question, hit star and one on your touchtone phone. Up next, we have Tushar Manudhane from Motilal Oswal Financial Services on the line. Please go ahead.

Tushar Manudhane analyst
#68

Thanks for giving me the chance to speak. Sir, regarding exports, your guidance points to revenue growth of roughly 12%-13%. Does that figure factor in currency depreciation too, or is it expressed in INR terms?

A.K. Jain executive
#69

Tushar, the guidance we provided is expressed in INR terms.

Tushar Manudhane analyst
#70

Understood. On the domestic formulation side, considering the raw material-linked pricing, could you share what price, volume, and new-launch growth we might expect for FY 2027?

A.K. Jain executive
#71

No, for the domestic branded business the guidance we provided is roughly 12%. Of that, perhaps 1%-2% might come from new product, with the rest split between price increase and volume.

Tushar Manudhane analyst
#72

Got it.

A.K. Jain executive
#73

If you look at Ipca's total material cost as a share of sales, sir, that figure stands at just 25%. A 1% rise, should it occur, would be offset by growth in the top line overall, as well as by the profitability of your products across domestic, ROW, and similar segments. Our expectation is that this ratio won't shift meaningfully — perhaps just 0.5% in one place or another. Yeah.

Tushar Manudhane analyst
#74

What's the trend been on freight costs, and will that show up around the gross margin line? My understanding is that it may be possible to pass along the raw material increase. How should we think about freight or logistics costs?

A.K. Jain executive
#75

Typically, for instance, our branded formulation business along with certain API business — all of that is done on, say, a C&F basis. A lot of other generic businesses take place where the freight is borne by the party. On the whole, I'd say our freight cost went up in the fourth quarter by roughly around 25%. That trend is still continuing at present as well. It will have some effect on profitability. As long as this issue of the Iran-U.S. kind of conflict persists — which is happening right now — the Strait of Hormuz and all that sort of thing. Oil prices are elevated. Wherever air shipments are involved, freight has multiplied now. Even securing cargo space availability at times takes a lot of time. Sometimes material sits for 10, 15 days. Availability itself is now becoming a problem for the various destinations. That issue persists, yeah.

Tushar Manudhane analyst
#76

So basically, will that affect Q1? On the whole, we figure that after that, over the next few quarters, we'll kind of bounce back.

A.K. Jain executive
#77

That’s going to have some effect. It will have some effect, but if the business improvement is there as well — for example, last year we grew by 10%, and this year our guidance is for growth of 12%-13% — that growth will offset all of it.

Tushar Manudhane analyst
#78

Okay, I understand, and I've got it. Thank you very much.

A.K. Jain executive
#79

The ratio of material cost to sales comes in at roughly 25%. When you factor that in, the gross margin addition on its own is going to be high. All of these costs ought to be offset.

Tushar Manudhane analyst
#80

Understood, sir. That's useful. Thanks.

Operator operator
#81

Thank you. A quick reminder for everyone on the line: if you'd like to pose a question, just hit star and one on your touchtone phone. With no more questions coming in from the participants, I'll now turn the conference back to management for their closing remarks.

A.K. Jain executive
#82

All right, with every question having been addressed, I believe it's time to wrap up this conference call. Thanks to all of you for joining.

Operator operator
#83

I appreciate it.

A.K. Jain executive
#84

Right.

Operator operator
#85

DAM Capital Advisors Limited has wrapped up this conference call. We appreciate everyone joining us, and at this point you're free to drop off the lines. Thanks so much.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Ipca Laboratories Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Ipca Laboratories Limited earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.